Relmada Therapeutics To Present New Preclinical Data On Its Psilocybin Program At AASLD The Liver Meeting 2023
Portfolio Pulse from Benzinga Newsdesk
Relmada Therapeutics, Inc. (NASDAQ:RLMD) announced new preclinical data on its novel psilocybin, showing significant reductions in liver fat content, plasma glucose levels, and body weight gain in a mice model. The company plans to initiate a single-ascending dose Phase 1 trial in patients in early 2024. The data will be presented at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2023.
October 11, 2023 | 12:41 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Relmada Therapeutics' new preclinical data on its novel psilocybin shows promising results, which could potentially lead to a new treatment for liver diseases. This could positively impact the company's stock in the short term.
The announcement of promising preclinical data is a positive development for Relmada Therapeutics. If the company's psilocybin proves to be an effective treatment for liver diseases, it could potentially open up a new revenue stream for the company, which would likely be viewed favorably by investors.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100